Subthalamic Nucleus Neuronal Firing Rate Increases with Parkinson's Disease Progression

Overview

Journal Mov Disord

Date 2011 May 5

PMID 21542021

Citations 31

Authors

Michael S Remple

Courtney H Bradenham

C Chris Kao

P David Charles

Joseph S Neimat

Peter E Konrad

Affiliations

Soon will be listed here.

Abstract

Parkinson's disease is a neurodegenerative disorder characterized by progressive loss of dopaminergic cells in the central nervous system, in particular the substantia nigra, resulting in an unrelenting loss of motor and nonmotor function. Animal models of Parkinson's disease reveal hyperactive neurons in the subthalamic nucleus that have increased firing rates and bursting activity compared with controls. Although subthalamic nucleus activity has been characterized in patients with advanced-stage Parkinson's disease, it has not been described in patients with early-stage Parkinson's disease. Here we present the results of subthalamic nucleus neuronal recordings from patients with early-stage Parkinson's disease (Hoehn and Yahr stage II) enrolled in an ongoing clinical trial compared with recordings from age- and sex-matched patients with advanced Parkinson's disease. Subthalamic nucleus neurons had a significantly lower firing rate in early versus advanced Parkinson's disease (28.7 vs 36.3 Hz; P<.01). The overall activity of the subthalamic nucleus was also significantly lower in early versus late Parkinson's disease, as measured by background neuronal noise (12.4 vs 14.0 mV; P<.05). No significant difference was identified between groups in the bursting or variability of neuronal firing in the subthalamic nucleus, as measured by a burst index or the interspike interval coefficient of variability. The results suggest that neuronal firing in the subthalamic nucleus increases with Parkinson's disease progression.

Citing Articles

Changes in electrophysiological aperiodic activity during cognitive control in Parkinson's disease.

Monchy N, Modolo J, Houvenaghel J, Voytek B, Duprez J Brain Commun. 2024; 6(5):fcae306.

PMID: 39301291 PMC: 11411214. DOI: 10.1093/braincomms/fcae306.

Why so slow? Models of parkinsonian bradykinesia.

Williams D Nat Rev Neurosci. 2024; 25(8):573-586.

PMID: 38937655 DOI: 10.1038/s41583-024-00830-0.

Brain Networks Involved in Sensory Perception in Parkinson's Disease: A Scoping Review.

Permezel F, Alty J, Harding I, Thyagarajan D Brain Sci. 2023; 13(11).

PMID: 38002513 PMC: 10669548. DOI: 10.3390/brainsci13111552.

Medication-invariant resting aperiodic and periodic neural activity in Parkinson's disease.

McKeown D, Jones M, Pihl C, Finley A, Kelley N, Baumann O Psychophysiology. 2023; 61(4):e14478.

PMID: 37937898 PMC: 11542173. DOI: 10.1111/psyp.14478.

Differences in subthalamic oscillatory activity in the two hemispheres associated with severity of Parkinson's disease.

Zhao X, Zhuang P, Hallett M, Zhang Y, Li J, Wen Y Front Aging Neurosci. 2023; 15:1185348.

PMID: 37700815 PMC: 10493322. DOI: 10.3389/fnagi.2023.1185348.

References

Albin R, Young A, Penney J . The functional anatomy of basal ganglia disorders. Trends Neurosci. 1989; 12(10):366-75. DOI: 10.1016/0166-2236(89)90074-x. View

Charles P, Gill C, Davis T, Konrad P, Benabid A . Is deep brain stimulation neuroprotective if applied early in the course of PD?. Nat Clin Pract Neurol. 2008; 4(8):424-6. DOI: 10.1038/ncpneuro0848. View

Rodriguez-Oroz M, Rodriguez M, Guridi J, Mewes K, Chockkman V, Vitek J . The subthalamic nucleus in Parkinson's disease: somatotopic organization and physiological characteristics. Brain. 2001; 124(Pt 9):1777-90. DOI: 10.1093/brain/124.9.1777. View

Fitzpatrick J, Konrad P, Nickele C, Cetinkaya E, Kao C . Accuracy of customized miniature stereotactic platforms. Stereotact Funct Neurosurg. 2005; 83(1):25-31. DOI: 10.1159/000085023. View

Bergman H, Wichmann T, DeLong M . Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science. 1990; 249(4975):1436-8. DOI: 10.1126/science.2402638. View

Hassani O, Mouroux M, Feger J . Increased subthalamic neuronal activity after nigral dopaminergic lesion independent of disinhibition via the globus pallidus. Neuroscience. 1996; 72(1):105-15. DOI: 10.1016/0306-4522(95)00535-8. View

Elias W, Durieux M, Huss D, Frysinger R . Dexmedetomidine and arousal affect subthalamic neurons. Mov Disord. 2008; 23(9):1317-20. DOI: 10.1002/mds.22080. View

Benabid A, Chabardes S, Mitrofanis J, Pollak P . Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson's disease. Lancet Neurol. 2008; 8(1):67-81. DOI: 10.1016/S1474-4422(08)70291-6. View

Bekker A, Sturaitis M . Dexmedetomidine for neurological surgery. Neurosurgery. 2005; 57(1 Suppl):1-10. DOI: 10.1227/01.neu.0000163476.42034.a1. View

10.

Hutchison W, Allan R, OPITZ H, Levy R, Dostrovsky J, Lang A . Neurophysiological identification of the subthalamic nucleus in surgery for Parkinson's disease. Ann Neurol. 1998; 44(4):622-8. DOI: 10.1002/ana.410440407. View

11.

Langston J, FORNO L, Rebert C, Irwin I . Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey. Brain Res. 1984; 292(2):390-4. DOI: 10.1016/0006-8993(84)90777-7. View

12.

Hobson D, Lang A, Martin W, Razmy A, Rivest J, Fleming J . Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. JAMA. 2002; 287(4):455-63. DOI: 10.1001/jama.287.4.455. View

13.

Alexander G, Crutcher M, DeLong M . Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, "prefrontal" and "limbic" functions. Prog Brain Res. 1990; 85:119-46. View

14.

Wichmann T, Soares J . Neuronal firing before and after burst discharges in the monkey basal ganglia is predictably patterned in the normal state and altered in parkinsonism. J Neurophysiol. 2005; 95(4):2120-33. DOI: 10.1152/jn.01013.2005. View

15.

Boraud T, Bezard E, Bioulac B, Gross C . From single extracellular unit recording in experimental and human Parkinsonism to the development of a functional concept of the role played by the basal ganglia in motor control. Prog Neurobiol. 2002; 66(4):265-83. DOI: 10.1016/s0301-0082(01)00033-8. View

16.

Gross R, Krack P, Rodriguez-Oroz M, Rezai A, Benabid A . Electrophysiological mapping for the implantation of deep brain stimulators for Parkinson's disease and tremor. Mov Disord. 2006; 21 Suppl 14:S259-83. DOI: 10.1002/mds.20960. View

17.

Bergman H, Wichmann T, Karmon B, DeLong M . The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism. J Neurophysiol. 1994; 72(2):507-20. DOI: 10.1152/jn.1994.72.2.507. View

18.

Magnin M, Morel A, Jeanmonod D . Single-unit analysis of the pallidum, thalamus and subthalamic nucleus in parkinsonian patients. Neuroscience. 2000; 96(3):549-64. DOI: 10.1016/s0306-4522(99)00583-7. View

19.

Galvan A, Wichmann T . Pathophysiology of parkinsonism. Clin Neurophysiol. 2008; 119(7):1459-74. PMC: 2467461. DOI: 10.1016/j.clinph.2008.03.017. View

20.

Benazzouz A, Gross C, Feger J, Boraud T, Bioulac B . Reversal of rigidity and improvement in motor performance by subthalamic high-frequency stimulation in MPTP-treated monkeys. Eur J Neurosci. 1993; 5(4):382-9. DOI: 10.1111/j.1460-9568.1993.tb00505.x. View